Drugs / LY03010
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05321602 | Sep 2021 → Sep 2022 | mood disorder, schizophrenia | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03751488 | Dec 2018 → Jul 2019 | schizoaffective disorder, schizophrenia | Luye Pharma Group Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY03010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03751488 ↗ |
| Route | Intramuscular | “LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.” NCT05321602 ↗ |